General
Preferred name
BECLAMIDE
Synonyms
N-Benzyl-3-chloropropionamide ()
Chloracon ()
Chlorakon ()
N-Benzyl-3-chloropropionamide, beta-chlorpropionamide ()
Nydrane ()
Neuracen ()
NSC-67062 ()
Beclamida ()
P&D ID
PD000707
CAS
501-68-8
Tags
available
drug
Drug Status
approved
experimental
investigational
Max Phase
2.0
Drug indication
Epilepsy
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Beclamide has been used for over three decades with little knowledge of how it acts in the CNS. In one study using rats, beclamide was seen to reduce striatal dopamine and serotonin levels and increase the levels of dopamine's major metabolites (and thus dopamine turnover), while reducing the levels of serotonin's major metabolite below detectable levels. A similar effect on neurotransmitter levels was seen in the rat frontal cortices. It is theorized that animal aggression is linked to levels of biogenic monoamines such as dopamine and serotonin, however the exact role is unclear. [A14453];
INDICATION Has been used in the management of epilepsy and epilepsy related behavioural disorders. It was used for generalised tonic-clonic seizures, and was not effective for absence seizures.; ; More recently focus has shifted to the use of beclamide in behavioural disorders. In mentally handicapped epileptic patients it has been found to decrease anxiety, antisocial and demanding behaviours, and impulsivity. Mood stabilizing effects were also noted. [2]; ; Additionally, due to its effects on monoamines, beclamide may have a potential place in treating conditions such as tardive dyskinesia and hyperkinetic syndromes. [2]
DESCRIPTION Beclamide is an active molecule with anticonvulsant activity, used as an anticonvulsant drug.
PRICE 29
DESCRIPTION Beclamide (Chlorakon) (N-benzyl-B-chloropropionamide) is a drug that possesses anticonvulsant activity. It is no longer used. It has been used as a sedative and as an anticonvulsant. It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalized tonic-clonic seizures. It was not effective for absence seizures. (TargetMol Bioactive Compound Library)
Compound Sets
11
ChEMBL Drugs
CHEMBL64195
Drug Repurposing Hub
DrugBank
DB09011
DrugCentral
291
DrugCentral Approved Drugs
291
DrugMatrix
MedChem Express Bioactive Compound Library
HY-B1185
ReFrame library
Selleckchem Bioactive Compound Library
beclamide
TargetMol Bioactive Compound Library
T1249
The Spectrum Collection
External IDs
26
Properties
(calculated by RDKit )
Molecular Weight
197.06
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
1
cLogP
1.93
TPSA
29.1
Fraction CSP3
0.3
Chiral centers
0.0
Largest ring
6.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
sedative, seizures
MOA
anticonvulsant
Target
Drug Derivative
Source data